a b s t r a c t 1,5 anhydroglucitol (1,5-AG), is a nonmetabolized 1-deoxy form of glucose, originate mainly from the diet. 1,5-AG is a biomarker to detect and magnify hyperglycemic excursions (postprandial hyperglycemia) in diabetic patients. Concentrations of 1,5-AG has been applied as supporting biomarker to diagnosis of the major forms of diabetes (type 1, type 2, and gestational). The serum 1,5-AG reference interval is relevant to the appropriate clinical application of this biomarker. This article contains data regards to serum concentration of the biomarker primarily for healthy subjects, capture from the literature, in different populations. Correlation analysis between 1,5-AG and markers associated with diabetes and its complication were presented. The data was complementary to the study "Reference intervals for serum 1,5-anhydroglucitol in children, adolescents, adults, and pregnant women" . The data present in this article improve the comparisons for 1,5-AG in different conditions and methodologies.
Specifications
.
Value of the data
Data will facilitate the comparison of 1,5-AG in different studies. The data showed the correlation among 1,5-AG and relevant parameters associated with diabetes. The data provide comparison between 1,5-AG reference interval in different ethnicities, ages, gender and methodologies.
These data provide information to researchers and clinical laboratory professionals to improve the 1,5-AG diagnostic use.
Data
In this article, we provide complementary data (urea, total protein and lipid profile) of the studied groups (Table 1) , correlation analysis (Table 2 ) and comparisons from the literature for serum 1,5-anhydroglycitol (1,5-AG) concentration, to our study. We proposed a reference interval (Tables 3 and  4) for this biomarker in children, adolescent, adults and pregnant women [2] . We studied healthy Euro-Brazilian subjects, classified as children (0-14 years old), adolescent (4 14 and o18 years old) and adults ( Z18 years old). Additionally, we analyzed pregnant women in four gestational periods, o23 weeks; 24-28 weeks, 29-32 weeks and 432 weeks of gestation. 1,5-AG was measure by enzymatic colorimetric method (Glycomark TM ; Tomen America, New York, NY, USA) in automated system Labmax 400 analyzer (Labtest Diagnostic).
The laboratory parameters, markers for kidney function (urea), nourishment (total protein) and lipid profile were compatible with healthy subjects (Table 1) .
The correlation in healthy subjects between 1,5-AG and glycemia, HbA1c, age, BMI and creatinine were weak or none (Table 2 ).
Experimental design, materials and methods

Study population
The population comprises 2303 unrelated Euro-Brazilian healthy subjects from Curitiba, State of Parana, South of Brazil [1] . All samples were obtained with the approval of the Ethics Committee of the Federal University of Parana.
Adult samples (n ¼ 922) were collected from blood bank donors. Children (n ¼ 580) and adolescent samples (n ¼ 496) were obtained from Public Schools. Healthy pregnant women (n ¼ 305) samples were obtained from the Curitiba Government Laboratory.
The normoglycemic criteria applied for selected subjects in the study were fasting glycemia o5.5 mmol/L with an HbA1c range of 20.2-36.6 mmol/mol (4.0-5.7%) for children, adolescents, and adults. For pregnant women a fasting blood glucose o5.1 mmol/L was applied to exclude gestational diabetes.
All subjects declared that were not using any medications or drugs.
Samples
Samples were serum obtained in non-fasting state for adults, children and adolescents, and fasting for those who were pregnant. Blood were collected in BD vacutainers SST II advance vacutainer with silica clot activator/gel (Becton Dickinson Co.). Bloods were separated in less than two hours from venipuncture and the serum stored in an ultrafreezer ( À 80°C).
Analytical methods
Concentrations of 1,5-AG were measured enzymatically with the Glycomark reagent (GlycoMark, Tomen America, New York, NY Inc.) in an automated system (Labmax 400 analyzer; Labtest. Diagnostics). The reaction details and methodology performance were described in Nowatzkea et al. [6] .
Clinical and laboratory parameters
Clinical data acquisition and analytical procedures, for laboratory data, have been reported previously [2] .
Data analysis
Descriptive statistics, correlation analysis and reference intervals were calculated with MedCalc MedCalc version 17.6 (MedCalc Statistical Software bvba, Ostend, Belgium). Probability values (p-values) less than 5% (p o 0.05) were considered significant for all tests.
